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Abstract
P. vivax and P. falciparum parasites display different tropism for host cells and induce very
different clinical symptoms and pathology, suggesting that the immune responses required
for protection may differ between these two species. However, no study has qualitatively
compared the immune responses to P. falciparum or P. vivax in humans following primary
exposure and infection. Here, we show that the two species differ in terms of the cellular
immune responses elicited following primary infection. Specifically, P. vivax induced the
expansion of a subset of CD8+ T cells expressing the activation marker CD38, whereas P.
falciparum induced the expansion of CD38+ CD4+ T cells. The CD38+ CD8+ T cell popula-
tion that expanded following P. vivax infection displayed greater cytotoxic potential com-
pared to CD38- CD8+ T cells, and compared to CD38+ CD8+ T cells circulating during P.
falciparum infection. We hypothesize that P. vivax infection leads to a stronger CD38+ CD8+
T cell activation because of its preferred tropism for MHC-I-expressing reticulocytes that,
unlike mature red blood cells, can present antigen directly to CD8+ T cells. This study pro-
vides the first line of evidence to suggest an effector role for CD8+ T cells in P. vivax blood-
stage immunity. It is also the first report of species-specific differences in the subset of T
cells that are expanded following primary Plasmodium infection, suggesting that malaria
vaccine development may require optimization according to the target parasite.
Trial Registration
anzctr.org.au ACTRN12612000814875; anzctr.org.au ACTRN12613000565741; anzctr.
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Author Summary
The specific immune responses that contribute to protective immunity in humans follow-
ing Plasmodium infection are yet to be fully characterized. The species P. vivax and P. fal-
ciparum account for most human infections, yet little is known about P. vivax specific
immune responses and whether they are similar to or distinct from P. falciparum. Here,
we establish that P. vivax and P. falciparum elicit distinct cellular immune responses fol-
lowing primary infection, with the expansion of a subset of CD38+ CD8+ T cells with a
cytotoxic potential in P. vivax but not in P. falciparum infection. This study provides the
first evidence for the activation of CD8+ T cells in P. vivax blood-stage infection and dem-
onstrates the existence of species-dependent host immune responses to malaria. These
findings have important implications for P. vivax vaccine development, and suggest that
future malaria vaccine studies should be adapted according to the target Plasmodium spp.
Introduction
Malaria vaccine research efforts have been directed predominantly at P. falciparum, since glob-
ally it is the major cause of malaria-related mortality [1]. However, it is now recognized that P.
vivax is poised to become the dominant species in areas where it is endemic [2] and can be
associated with severe pathology [2,3]. Yet, compared to what is known about responses to P.
falciparum, little is known about immune responses to P. vivax infection. This lack in knowl-
edge is due in part to confounders that are present in samples from naturally-infected individ-
uals living in malaria-endemic regions where parasitic co-infections and cross-species
immunity are present; and technical difficulties associated with experimental infection of
humans due to a lack of a method for the continuous in vitro culture of P. vivax [4]. It has been
generally assumed that P. vivax would elicit similar immune responses compared to P. falcipa-
rum. However, the two parasites display very different features in terms of life cycle, invasion
mechanism and immunopathology [2,3,5] and thus may generate distinct host specific
immune responses. A few studies have compared global frequencies of circulating lymphocyte
populations during P. falciparum or P. vivax infection in naturally infected humans [6,7], but
have not investigated their activated or effector phenotype.
The recent establishment of different models of Controlled Human Malaria Infection
(CHMI) provides the opportunity to obtain samples from malaria-naive healthy volunteers
following first exposure to Plasmodium blood-stage parasites, thereby greatly enhancing our
understanding of the host-parasite immune response [8,9]. Until recently, such experimental
infection studies could be done only with P. falciparum due to the lack of a continuous in vitro
culture system of P. vivax as a source of parasitized red blood cells [8]. Recently, however, a
cell bank of cryopreserved P. vivax infected erythrocytes was successfully derived from a natu-
rally-infected individual and used to experimentally infect malaria-naive healthy adult volun-
teers, establishing for the first time a CHMI model with P. vivax [10].
Here, we have taken advantage of this novel resource to compare cellular immune
responses generated following experimental blood-stage infection of naive volunteers with P.
vivax or P. falciparum. Overall, we found marked differences in the immune profiles generated
following infection with the two species. Specifically, P. vivax but not P. falciparum infection
led to the expansion of a specific subset of CD8+ T cells which were associated with an acti-
vated phenotype and cytotoxic potential. This study enhances our understanding of P. vivax
associated immunity and Plasmodium species-specific immunity, identifying for the first time
components of the immune response to blood-stage infection that are species-specific.
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Methods
Ethics
Experimental infection of malaria-naive healthy adult volunteers was undertaken at
QPharm Pty Ltd (Brisbane, Australia); all clinical studies were registered on the Austra-
lian and New Zealand Clinical Trials Registry (ANZCTR): P. falciparum clinical trial ID
numbers ACTRN12612000814875, ACTRN12613000565741, ACTRN12613001040752
and NCT02281344; and P. vivax clinical trial numbers ACTRN12612001096842 and
ACTRN12613001008718, with written informed consent and approval of the QIMR Ber-
ghofer Medical Research Institute Human Research Ethics Committee (QIMRB-HREC)
and the Western Institutional Review Board (ethics board for the trial sponsor, Program
for Appropriate Technology in Health, PATH).
Sample collection and processing
Inoculum preparation, volunteer recruitment, infection, monitoring and treatment were per-
formed as described previously for P. falciparum [11] or P. vivax [10]. In brief, healthy
malaria-naive individuals were intravenously inoculated with freshly thawed P. falciparum
3D7 or P. vivax parasitized erythrocytes and treated with anti-malarial drugs when the parasi-
temia exceeded the approximate threshold of 10,000 parasites/mL, at day 7–8 post-infection or
day 14 post-infection for P. falciparum or P. vivax, respectively. The infecting dose for P. falcip-
arum was 1,800 viable parasitized red blood cells. Parasite growth modeling using in silico
analysis estimated that the infecting dose for P. vivax was 15 fold lower compared to P. falcipa-
rum (Khoury D &McCarthy JS, in preparation). Blood samples were collected prior to infec-
tion, at day 7 post-infection for P. falciparum infected volunteers, and day 14 post-infection for
P. vivax infected volunteers. Peripheral blood collected in Lithium Heparin Vacutainers (Bec-
ton Dickinson) was either used directly for flow cytometry analysis, or peripheral blood mono-
nuclear cells (PBMC) isolated using standard Ficoll density gradient centrifugation.
Determination of parasitemia and kinetics
Parasitemia was determined using a consensus P. falciparum or P. vivax species-specific quan-
titative PCR assay as previously described [12]. Parasite levels were assessed once daily until
day four post-infection and then twice daily until treatment. All samples were batch tested in
triplicate together after each study completion. Limit of detection was 64 parasites/ml [12].
Exponential growth equation fitting parasitemia kinetics for P. falciparum or P. vivax infected
volunteers was calculated with GraphPad Prism (version 6.0).
Ex vivo phenotyping of lymphocytes by flow cytometry on whole blood
Staining buffer was PBS supplemented with 0.5% FCS and 4 mM EDTA. Whole blood col-
lected in Lithium Heparin vacutainers was lysed and fixed with BD FACS lysing solution (Bec-
ton Dickinson) and lymphocytes permeabilized with BD FACS permeabilising solution 2
(Becton Dickinson) according to the manufacturer’s instructions. Cells were then resuspended
in 50 μl of staining buffer containing anti-human CD4-BV510 (Becton Dickinson, 1:200 dilu-
tion), anti-human CD8-APC-H7 (Becton Dickinson, 1:400 dilution), anti-human CD19-
PE-Cy7 (Biolegend, 1:200 dilution), anti-human CD38-APC (Biolegend, 1:400 dilution),
anti-human Perforin-PE (Biolegend, 1:400 dilution), anti-human Granzyme B-Pacific Blue
(Biolegend, 1:400 dilution) and 1 μl of human Fc receptor blocking solution (Human TruStain
FcX, Biolegend) for 30 minutes at room temperature, washed and resuspended in staining
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buffer before acquisition on LSR Fortessa 4 (Becton Dickinson) with Diva software. FlowJo
software version 6.0 was used for gating.
Cell sorting
CD38+ CD8+ T cells, CD38- CD8+ T cells as well as CD8- cells were sorted from freshly isolated
PBMC. Approximately 10x106 cells were resuspended in 50 μl of staining buffer containing
anti-human CD4-BV510 (Biolegend, 1:200 dilution), anti-human CD8-APC-H7 (Becton
Dickinson, 1:400 dilution) and anti-human CD38-PerCpCy5.5 (Biolegend, 1:400 dilution) for
20 minutes at 4˚C, washed and resuspended in staining buffer. Just before the sorting, 1 μg/mL
of propidium iodide (Sigma-Aldrich) was added to allow for assessment of viability. Pi-CD8+
CD4-CD38+, Pi-CD8+CD4-CD38-, and Pi-CD8- cells were sorted using a BD Aria III cell sorter
(Becton Dickinson) directly in staining buffer and kept on ice until further use for in vitro
assays.
CD107a-based degranulation assay
Sorted CD38+ and CD38- CD8+ T cells were plated at 50,000 cells/well in RPMI 1640 contain-
ing 25 mM Hepes, 2 mM L-glutamine (Invitrogen), and supplemented with 10 units/mL of
Penicillin (Life Technologies), 10 μg/mL of Streptomycin (Life Technologies) and 10% fetal
bovine serum (Life Technologies) in a 96-well plate pre-coated overnight with 10 μg/mL of
anti-human CD3 OKT3 antibody (Biolegend) together with 0.75x106 cells/mL autologous
CD8- cells, anti-human CD107a-FITC (Biolegend, 1:200 dilution) and 1 μg/mL of co-stimula-
tory antibodies anti-human CD28 and anti-human CD49d (Becton Dickinson) for 5 hours at
37˚C in an atmosphere of 5% C02. Following stimulation, cells were resuspended in 20 μl of
staining buffer containing anti-human CD4-BV510 (Biolegend, 1:200 dilution), anti-human
CD8-APC-H7 (Becton Dickinson, 1:400 dilution) for 20 minutes at 4˚C, washed and resus-
pended in staining buffer before acquisition on LSR Fortessa 4 (Becton Dickinson) with Diva
software. FlowJo version 6.0 was used for gating.
Results
P. falciparum and P. vivax primary blood-stage infection in humans
generated similar parasitemia curves
P. falciparum and P. vivax experimental infection of malaria-naive volunteers was performed
under similar procedures [10,11]. However, due to logistical reasons associated with parasite
density in the inoculum stock, and a lack of a continuous in vitro culture system for P. vivax
[4], the infecting dose for P. vivax was estimated to be 15-fold lower than that used in the P. fal-
ciparum studies (Khoury D &McCarthy JS, in preparation). Demographics of P. falciparum
and P. vivax infected volunteers were comparable in term of age, gender, BMI and ethnicity
(S1 Table).
Parasitemia growth curves determined by quantitative PCR (qPCR) from P. falciparum and
P. vivax experimental infection studies were similar for both parasites (Fig 1 and Table 1)
except for the delayed onset of detectable blood-stage parasitemia with P. vivax. Specifically, P.
falciparum parasites were detected as early as day 4 of infection whereas P. vivax parasites were
detected at day 8 of infection, consistent with the differences in the size of the starting inocula.
Interestingly, all individuals infected with P. vivax developed symptoms of malaria before the
time of treatment while more than 40% of P. falciparum infected individuals were asymptom-
atic until anti-malarial drug administration (S2 Table).
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P. falciparum and P. vivax primary blood-stage infection in humans
elicited qualitatively different immune responses
In order to compare cellular immune responses to infection between P. falciparum and P.
vivax infected volunteers, we determined the phenotype of lymphocytes ex vivo from whole
blood samples obtained prior to infection and during infection once the parasitemia exceeded
10,000 parasites/mL (which corresponded to day 7 and day 14 for P. falciparum and P. vivax
infected volunteers, respectively). CD38 is a surface glycoprotein that modulates cell adhesion,
signal transduction and intracellular Ca2+ levels, and is specifically upregulated on lympho-
cytes following activation [13]. We have recently shown that the frequency of CD38+ T cells
and B cells circulating in the peripheral blood of test volunteers was dynamically regulated
during experimental blood-stage infection with P. falciparum and that the expansion of CD38+
CD4+ T cells following infection was inversely correlated with parasite burden [14]. Thus, we
compared the frequencies of CD38+ T cells and B cells circulating before and after infection in
P. falciparum or P. vivax infected volunteers. There was a higher frequency of CD38+ CD4+ T
cells circulating following infection in P. falciparum but not P. vivax infected volunteers (Fig
2A). Conversely, P. vivax infection but not P. falciparum elicited a higher frequency of
Fig 1. Kinetics of parasite levels during experimental blood-stage infection with P. falciparum or P. vivax. Malaria-naive
volunteers were infected intravenously at day 0 with freshly thawed cryopreserved P. falciparum or P. vivax infected erythrocytes.
Parasite growth modeling using in silico analysis estimated that the P. vivax infecting dose was 15 times lower compared to the P.
falciparum infecting dose (Khoury D & McCarthy JS, in preparation). Parasite levels in peripheral blood of infected volunteers were
determined using consensus Plasmodium species-specific qPCR as previously described [12]. Blood samples used to assess
immune responses were collected prior to infection. Graphs show mean data from 19 volunteers from three independent cohorts
(P. falciparum) and 8 volunteers from four independent cohorts (P. vivax); error bars indicate SD.
doi:10.1371/journal.pntd.0005031.g001
Table 1. Statistics of exponential growth equation fitting the parasitemia curves of P. falciparum and
P. vivax infected naïve volunteers.
P. falciparum P. vivax
Growth rate (days-1) 2.2 [1.5–2.9] 1.9 [1.3–2.5]
Doubling time (days) 0.31 [0.24–0.46] 0.36 [0.27–0.54]
R square 0.60 0.63
doi:10.1371/journal.pntd.0005031.t001
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circulating CD38+ CD8+ T cells (Fig 2B). No significant differences were observed in the fre-
quency of CD38+ B cells circulating following infection with P. falciparum or P. vivax (Fig 2C).
There was no correlation between the expansion of CD38+ CD8+ T cells following infection
and parasite burden (S1 Fig). Overall, these data suggest that the quality of the immune
response generated following primary blood-stage infection in humans is Plasmodium species-
dependent.
CD38+ CD8+ T cells expanded in P. vivax infection are associated with a
cytotoxic function
Since very little information on P. vivax protective immune responses is available, we aimed to
further understand the contribution of CD38+ CD8+ T cells to P. vivax blood-stage immunity.
Effector CD8+ T cells perform classical cytotoxic functions by killing infected cells through
perforin-mediated dependent mechanisms. To determine the cytotoxic potential of CD38+
CD8+ T cells generated during P. vivax infection, we measured their intracellular expression of
granzyme B and perforin by flow cytometry, in an independent cohort (n = 2 because of logis-
tics associated with vivax experimental infection). We found similar expression of granzyme B
Fig 2. The frequency of CD38+ T cells and B cells circulating during experimental blood-stage infection with P. falciparum or P. vivax. Blood
samples were collected from malaria-naive volunteers prior to (pre) and post-infection (post) with P. falciparum or P. vivax infected erythrocytes, as
described in legend to Fig 1. The frequency of CD38+ cells was determined by flow cytometry in (A) CD4+ T cells, (B) CD8+ T cells, or (C) CD19+ B cells.
Differences in cell frequencies between pre- and post-infection were determined using the non-parametric paired Wilcoxon test. Plots show representative
staining of CD38 from one P. falciparum infected volunteer and one P. vivax infected volunteer. Graphs show paired data from 19 volunteers from three
independent cohorts (P. falciparum) and 8 volunteers from four independent cohorts (P. vivax); ****, p < 0.0001; **, p < 0.01.
doi:10.1371/journal.pntd.0005031.g002
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and perforin in CD38+ and CD38- CD8+ T cells before infection (Fig 3A and 3B). However,
post-infection, CD38+ CD8+ T cells had a greater expression of granzyme B and perforin com-
pared to CD38- CD8+ T cells (Fig 3A and 3B). Additionally, CD38+ CD8+ T cells circulating
during infection contained a higher amount of granzyme B and perforin in P. vivax infected
volunteers compared to P. falciparum infected volunteers (Fig 3C and 3D) whereas no differ-
ences were observed prior to infection.
In order to further investigate the cytotoxic potential of CD38+ CD8+ T cells and CD38-
CD8+ T cells circulating during P. vivax infection, we tested their ability to degranulate in vitro
following TCR stimulation. Prior to infection, CD38+ and CD38- CD8+ T cells had the same
ability to degranulate, whereas post-infection CD38+ CD8+ T cells had a higher degranulation
compared to CD38- CD8+ T cells (Fig 4).
Overall, these findings suggest that CD38+ CD8+ T cells have a greater cytotoxic potential
compared to CD38- CD8+ T cells and that this cytotoxic function is specifically activated in the
CD38+ CD8+ T cells circulating during P. vivax infection but not P. falciparum infection.
Discussion
Herein we report on the first study to compare the quality of cellular immune responses elic-
ited in humans by experimental blood-stage infection with P. vivax or P. falciparum. In this
study we utilized a model of controlled infection of malaria-naive human volunteers, thereby
avoiding potential confounders of pre-existing immunity and cross-species immunity. We
found marked differences between responses to the two Plasmodium species in terms of the
phenotype of T cells that expanded during infection. P. falciparum infection elicited a signifi-
cant expansion of CD38+ CD4+ T cells whereas P. vivax infection led to the expansion of
CD38+ CD8+ T cells. We have recently shown that the frequency of circulating CD38+ CD4+ T
cells was significantly increased following experimental infection with P. falciparum and
inversely correlated with parasite levels [14]. Here we show that P. vivax blood-stage infection
elicited a substantially different type of immune response compared to P. falciparum, with sig-
nificant changes in the CD8+ T cell compartment rather than in the CD4+ T cell compartment.
There was no significant association between the expansion of CD38+ CD8+ T cells and para-
site burden in P. vivax infected volunteers, suggesting that the expansion of CD38+ CD4+ T
cells in P. falciparum infection and the expansion of CD38+ CD8+ T cells in P. vivax infection
might have distinct contributions to the immune response to blood-stage infection.
A possible explanation for the qualitative differences observed between P. falciparum and P.
vivax associated immune responses may relate to their distinct tropism during blood-stage
infection. P. vivax merozoites preferentially invade reticulocytes [15] which, although they are
enucleated, still express MHC-I molecules which remain from the nucleated reticuloblast
stage. This is in contrast to mature erythrocytes that have completely lost expression of MHC
molecules. Previous work using a genetically engineered mouse model of murine malaria has
shown that CD8+ T cells can be activated by parasitized erythroblasts but not parasitized
mature red blood cells through MHC-I dependent mechanisms [16]. Thus, we hypothesize
that the higher proportion of infected reticulocytes in P. vivax infection leads to the activation
of a higher proportion of CD38+ CD8+ T cells in an MHC-I dependent manner in comparison
to P. falciparum infection.
While it is established that CD4+ T cells and parasite-specific antibodies are critical for pro-
tective immune responses to blood-stage malaria [17], the contribution of CD8+ T cells is less
clear. Studies in mice have shown that CD8+ T cells were activated and associated with protec-
tive function in lethal [18] or chronic [19] blood-stage malaria. However, no association
between CD8+ T cells and protective immunity to primary blood-stage infection in humans
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Fig 3. Granzyme B and perforin expression in circulating CD38+ CD8+ T cells following P. vivax blood-stage infection. Blood
samples were collected from malaria-naive volunteers prior to and post-infection with P. falciparum or P. vivax infected erythrocytes, as
described in legend to Fig 1. The expression of granzyme B and perforin within CD38+ CD8+ T cells and CD38- CD8+ T cells was
determined by flow cytometry. (A) Representative staining of granzyme B and perforin in CD38+ and CD38- CD8+ T cells from one P. vivax
infected volunteer. (B) The frequency of cells expressing granzyme B and perforin in CD38+ or CD38- CD8+ T cells circulating pre- and
post-infection with P. vivax. (C) Representative staining of granzyme B and perforin in circulating CD38+ CD8+ T cells from one P.
falciparum infected volunteer and one P. vivax infected volunteer. (D) The frequency of cells expressing granzyme B and perforin in
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has been reported yet. Our data suggest that the CD38+ CD8+ T cells that specifically expand
during P. vivax infection display increased cytotoxic function compared to other CD8+ T cells.
Hence their function might be to kill parasitized reticulocytes through MHC-I dependent and
perforin-mediated mechanisms. This proposal is further supported by the enhanced expres-
sion of cytotoxic molecules observed in CD38+ CD8+ T cells circulating during P. vivax com-
pared to P. falciparum infection. In contrast, we could not identify an expansion of cytotoxic
CD8+ T cell population following P. falciparum infection of malaria-naïve volunteers.
These findings have important implications in regard to P. vivax vaccine development.
Indeed, most efforts so far have been directed toward the direct translation of the findings
associated with P. falciparum vaccine development to P. vivax [20] (e.g. the use of ortholog
antigens that were shown to be protective against P. falciparum). Here we show that P. falcipa-
rum and P. vivax elicit qualitatively different immune responses and are likely to require dis-
tinct vaccine-induced immune responses for protection. Thus, the immunization strategy may
need to be adapted for each Plasmodium species to mount optimal protective immune
responses, and the design of a universal vaccine conferring protection against multiple Plasmo-
dium species might be conceptually more challenging than initially thought.
In conclusion, in this study we report that primary exposure of humans to different Plasmo-
dium species elicited qualitatively distinct immune responses: P. falciparum infection gener-
ated changes in CD4+ T cells whereas P. vivax preferentially activated a subset of CD8+ T cells
expressing the activation marker CD38 and associated with a cytotoxic function. The specific
expansion of CD38+ CD8+ T cells following P. vivax infection might be due to the preference
for P. vivax merozoites to infect reticulocytes which can activate CD8+ T cells through MHC-I
circulating CD38+ CD8+ T cells pre- or post-infection in P. vivax or P. falciparum infected volunteers. Graphs show mean data from 6
volunteers (P. falciparum) or 2 volunteers (P. vivax); error bars indicate SD.
doi:10.1371/journal.pntd.0005031.g003
Fig 4. Degranulation in circulating CD38+ and CD38- CD8+ T cells following P. vivax blood-stage
infection. Blood samples were collected from malaria-naive volunteers prior to and post-infection with P.
falciparum or P. vivax infected erythrocytes, as described in legend to Fig 1. Degranulation of CD38+ and
CD38- CD8+ T cells was determined by flow cytometry using a CD107a-based degranulation assay on sorted
cells after five hours stimulation with plate-bound anti-human CD3 (10 μg/mL). (A) Representative staining of
CD107a in circulating CD38+ and CD38- CD8+ T cells from one P. vivax infected volunteer. (B) Frequency of
CD107a+ cells after stimulation (background subtracted) in circulating CD38+ and CD38- CD8+ T cells pre- or
post-infection in P. vivax infected volunteers. Graphs show mean data from 2 volunteers.
doi:10.1371/journal.pntd.0005031.g004
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dependent mechanisms. Overall our data are consistent with the proposal that protective
immune responses to Plasmodium are species-dependent. These findings have important
implications for malaria vaccine development strategies.
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